Leqvio (inclisiran) is approved by MHLW for familial and non-familial hypercholesterolemia and for patients who are at a high risk of developing cardiovascular events
Leqvio (inclisiran), became the first siRNA therapy for dyslipidemia approved in Japan
The drug was approved for familial and non-familial hypercholesterolemia and is intended for patients who are at a high risk of developing cardiovascular events and who also show insufficient responses to or are not suited for treatment with HMG-CoA reductase inhibitors. The drug was also approved for the indication of familial and non-familial hypercholesterolemia.
It will be used in patients who meet both of the following requirements: 1) having a high risk of developing cardiovascular events and 2) showing insufficient responses to or being not suited for treatment with HMG-CoA reductase inhibitors. Optimal use promotion guidelines will be compiled to specify more detailed eligibility criteria for facilities and patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.